These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 17478016

  • 1. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response.
    Rosa R, Marques C, Rodrigues OR, Santos-Gomes GM.
    Vaccine; 2007 Jun 06; 25(23):4525-32. PubMed ID: 17478016
    [Abstract] [Full Text] [Related]

  • 2. Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response.
    Rosa R, Rodrigues OR, Marques C, Santos-Gomes GM.
    Exp Parasitol; 2005 Feb 06; 109(2):106-14. PubMed ID: 15687017
    [Abstract] [Full Text] [Related]

  • 3. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug 06; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 4. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V.
    Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL.
    Int J Parasitol; 2005 Jan 22; 35(1):63-73. PubMed ID: 15619517
    [Abstract] [Full Text] [Related]

  • 12. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M, Margaroni M, Karagouni E.
    Vaccine; 2011 Jul 12; 29(31):5053-64. PubMed ID: 21569815
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 12; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 16. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunization with the Leishmania infantum recombinant cyclophilin protein 1 confers partial protection to subsequent parasite infection and generates specific memory T cells.
    Santos-Gomes GM, Rodrigues A, Teixeira F, Carreira J, Alexandre-Pires G, Carvalho S, Santos-Mateus D, Martins C, Vale-Gato I, Marques C, Tomás AM.
    Vaccine; 2014 Mar 05; 32(11):1247-53. PubMed ID: 24486368
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.